Medical Pharmaceuticals

July 17, 2026

AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…

HHealthcare

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

July 15, 2026

Mississauga, ON, July 15, 2026 /PRNewswire/ – Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare…

TTechnology

June 29, 2026

Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohorts…

HHealth

June 6, 2026

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney…

HHealth

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

June 6, 2026

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach…

MMedication

Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®

May 26, 2026

MISSISSAUGA, ON, May 26, 2026 /CNW/ – Novo Nordisk Canada is announcing that effective Friday, May 29, 2026,…

HHealthcare

Vi Launches Suite of AI Agents for Healthcare, Life Sciences, and Wellness Enterprises; Completes $145M Transaction at $1.64B Valuation

May 20, 2026

NEW YORK, May 19, 2026 /PRNewswire/ — Vi, the enterprise-AI platform for health, today announced a new suite…

MMedication

May 17, 2026

In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all…

HHealthcare

Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada

May 15, 2026

TORONTO, May 14, 2026 /PRNewswire/ – Apotex Inc. (“Apotex” or the “Company”), the largest Canadian‑based global health company,…

HHealthcare

April 20, 2026

Kelonia’s lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for…

HHealth

April 9, 2026

Phase 2a ROCSTAR study is evaluating ROC-101, a potential first-in-class oral pan-ROCK inhibitor, in PAH and ILD-PH patients…

HHealthcare

Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer

April 7, 2026

Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company…

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

BillionToOne’s Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®

Vi Launches Suite of AI Agents for Healthcare, Life Sciences, and Wellness Enterprises; Completes $145M Transaction at $1.64B Valuation

Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials

Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Hypertension

Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer